#Breaking
Same-day regulatory or trial readout coverage.
Retatrutide access opens case by case
A US registry now lists individual-patient retatrutide expanded access as available under narrow criteria. It is not approval or broad availability.
Lilly obesity campaign and GLP-1 access
Lilly's new obesity campaign brings older adults into view as CMS prepares a limited Medicare GLP-1 access demonstration.
Retatrutide: US compassionate use explained
Retatrutide is investigational. The US has opened a compassionate use pathway after Trump speculation. Here is what that means and who may qualify.
Semaglutide kidney outcomes: pooled trials
A prespecified pooled analysis of 30,787 participants finds semaglutide cuts serious kidney events by 16% (HR 0.84) vs placebo.
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.